Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a sell rating in a research note released on Saturday morning.

Other equities analysts also recently issued research reports about the stock. Stifel Nicolaus set a $30.00 price target on shares of Trevi Therapeutics in a report on Friday. D. Boral Capital reissued a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday, April 17th. Needham & Company LLC cut their price objective on shares of Trevi Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday. Morgan Stanley restated an “overweight” rating and set a $20.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $22.90.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $14.50 on Friday. Trevi Therapeutics has a 1 year low of $5.38 and a 1 year high of $16.12. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -45.31 and a beta of 1.07. The firm has a fifty day moving average of $12.69 and a 200-day moving average of $11.95.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Analysts predict that Trevi Therapeutics will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Peregrine Capital Management LLC acquired a new stake in Trevi Therapeutics in the 3rd quarter valued at about $5,677,000. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in Trevi Therapeutics by 9.7% in the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock valued at $11,500,000 after acquiring an additional 110,672 shares during the last quarter. Pictet Asset Management Holding SA lifted its holdings in Trevi Therapeutics by 13,507.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock valued at $19,181,000 after acquiring an additional 1,520,754 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Trevi Therapeutics by 93.0% in the 4th quarter. SG Americas Securities LLC now owns 124,562 shares of the company’s stock valued at $1,560,000 after acquiring an additional 60,017 shares during the last quarter. Finally, Optimize Financial Inc acquired a new stake in Trevi Therapeutics in the 3rd quarter valued at about $554,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Key Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: HC Wainwright lifted near-term EPS estimates for Q2 2026 to ($0.11) from ($0.12), suggesting modestly better expected profitability. Trevi Therapeutics Q1 2026 Earnings Call Transcript
• Positive Sentiment: The firm also increased its Q3 2026 EPS estimate to ($0.14) from ($0.17), Q4 2026 to ($0.15) from ($0.17), and FY2026 to ($0.47) from ($0.54).
• Positive Sentiment: HC Wainwright kept a bullish long-term view, raising its FY2027 estimate to ($0.57) from ($0.63) and FY2028 to ($0.63) from ($0.66), while maintaining the same $21 price target.
• Neutral Sentiment: The analyst trimmed its FY2029 estimate to $0.70 from $0.79 in one report, but the overall tone remained constructive.
• Neutral Sentiment: Trevi recently reported a Q1 loss of ($0.09) per share, slightly wider than expectations, so the stock’s move appears driven more by improved forward estimates and analyst confidence than by the latest earnings print.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.